PMC9638685_01
Skin lesion on the scalp at diagnosis.
10.1177_23247096221127114-fig1.jpg
PMC9638685_01_10.1177_23247096221127114-fig1.jpg
fig1-23247096221127114
The skin lesion on the patient's scalp is shown in Figure 1.
Bone marrow aspirate prior to treatment with vyxeos. (A) Clot aspirate
section at 20x. (B) Clot aspirate at 10x. (C) and (D) Bone marrow aspirate
demonstrating blasts.
10.1177_23247096221127114-fig2.jpg
PMC9638685_01_10.1177_23247096221127114-fig2.jpg
fig2-23247096221127114
The bone marrow aspirate at relapse is shown in Figure 2.
Circulating blast in peripheral smear.
10.1177_23247096221127114-fig3.jpg
PMC9638685_01_10.1177_23247096221127114-fig3.jpg
fig3-23247096221127114
Figure 3 shows a circulating blast on the peripheral smear.
Flow cytometry demonstrating the immunophenotype at relapse.
10.1177_23247096221127114-fig4.jpg
PMC9638685_01_10.1177_23247096221127114-fig4.jpg
fig4-23247096221127114
The immunophenotype at relapse is shown in Figure 4.
Bone marrow aspirate a month after vyxeos showing hypocellular marrow at
10x.
10.1177_23247096221127114-fig5.jpg
PMC9638685_01_10.1177_23247096221127114-fig5.jpg
fig5-23247096221127114
Figure 5 demonstrates the bone marrow aspirate done a month after vyxeos. His bone marrow showed a complete response to vyxeos with no evidence of BPDCN (Figure 5).